Hepatitis Monthly

Published by: Kowsar

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C

Mahdiyar Pouresmaeeli 1 , 2 , Seyed Moayed Alavian 1 , 2 , * , Maryam Keshvari 3 , Shima Salimi 1 , 2 and Leila Mehrnoush 1 , 2
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran, IR Iran
2 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
3 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
Article information
  • Hepatitis Monthly: September 01, 2015, 15 (9); e30780
  • Published Online: September 29, 2015
  • Article Type: Research Article
  • Received: June 15, 2015
  • Revised: August 18, 2015
  • Accepted: August 19, 2015
  • DOI: 10.5812/hepatmon.30780

To Cite: Pouresmaeeli M, Alavian S M, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C, Hepat Mon. 2015 ; 15(9):e30780. doi: 10.5812/hepatmon.30780.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hepatitis C.
  • 2. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010; 14 Suppl 3-6[DOI][PubMed]
  • 3. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 4. Guidelines for the screening, Care and Treatment of Persons with Hepatitis C Infection.
  • 5. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012; 12(9): 717-28[DOI][PubMed]
  • 6. Gellad ZF, Reed SD, Muir AJ. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther. 2012; 17(6 Pt B): 1189-99[DOI][PubMed]
  • 7. El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, et al. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepat Mon. 2013; 13(5)[DOI][PubMed]
  • 8. Romero-Gomez M, Planas R, Ampuero J, Sola R, Garcia-Samaniego J, Diago M, et al. Meta-analysis: pegylated interferon alpha-2a achieves higher early virological responses than alpha-2b in chronic hepatitis C. Aliment Pharmacol Ther. 2013; 37(11): 1065-73[DOI][PubMed]
  • 9. Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C : a meta-analysis. Drugs. 2013; 73(3): 263-77[DOI][PubMed]
  • 10. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010; 10(2): 121-31[PubMed]
  • 11. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010; 51(4): 1176-84[DOI][PubMed]
  • 12. Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011; 56(8): 2221-6[DOI][PubMed]
  • 13. Dogan UB, Atabay A, Akin MS, Yalaki S. The comparison of the efficacy of pegylated interferon alpha-2a and alpha-2b in chronic hepatitis C patients with genotype 1. Eur J Gastroenterol Hepatol. 2013; 25(9): 1082-5[DOI][PubMed]
  • 14. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6): 580-93[DOI][PubMed]
  • 15. Jin YJ, Lee JW, Lee JI, Park SH, Park CK, Kim YS, et al. Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol. 2013; 13: 74[DOI][PubMed]
  • 16. Brochot E, Nguyen-Khac E, Duverlie G. Equal efficacy between the two types of peginterferon on HCV: a matter of relapse? Antiviral Res. 2013; 98(1): 1-3[DOI][PubMed]
  • 17. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009; 24(3): 336-45[DOI][PubMed]
  • 18. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000; 87(5): 741-9[PubMed]
  • 19. Jahanbakhsh Sefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013; 13(1)[DOI][PubMed]
  • 20. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010; 13(4): 306-12[PubMed]
  • 21. Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multicenter Study. Middle East J Dig Dis. 2011; 3(2): 110-4[PubMed]
  • 22. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 23. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013; 56(7): 961-7[DOI][PubMed]
  • 24. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010; 138(1): 108-15[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments